NOVEL REGULATORY PATHWAYS FOR
HEALTHSPAN PRODUCTS
At the Longevity Partnering Forum, Kitalys Institute Co-Founder and President Alexander Fleming, MD, outlined potential regulatory pathways for healthspan products. You can see his presentation below.
Dr. Fleming began with an explanation of why jumping directly to a sweeping “healthspan” indication is not yet realistic. He instead laid out a practical regulatory path: begin with measurable benefits in early or age-related disease, build evidence across additional indications, and progressively move toward healthier populations and broader prevention. His presentation confronted a central challenge for longevity medicine: trials in healthy people could require enormous numbers of participants and years of follow-up, making the development of validated surrogate endpoints potentially transformative. Yet validating those biomarkers creates its own Catch-22, requiring interventions proven to deliver meaningful clinical benefits.
Ultimately, Dr Fleming emphasized, the path to recognized healthspan therapies cannot be created by FDA alone. Scientists, clinicians, regulators, and industry must build the endpoints, evidence, and regulatory frameworks capable of turning today’s longevity science into tomorrow’s disease-prevention medicines.